UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents

Cancer chemotherapy and pharmacology, 2019-06, Vol.83 (6), p.1159-1173

2019

Volltextzugriff (PDF)

Using thrombocytopenia modeling to investigate the mechanisms underlying platelet depletion induced by pan‐proteasome inhibitors

CPT: pharmacometrics and systems pharmacology, 2022-05, Vol.11 (5), p.594-603

2022

Volltextzugriff (PDF)

Model‐Based Evaluation of Radiation and Radiosensitizing Agents in Oncology

CPT: pharmacometrics and systems pharmacology, 2018-01, Vol.7 (1), p.51-58

2018

Volltextzugriff (PDF)

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

Clinical cancer research, 2020-03, Vol.26 (6), p.1237-1246

2020

Volltextzugriff (PDF)

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

British journal of cancer, 2021-02, Vol.124 (4), p.728-735

2021

Volltextzugriff (PDF)

Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis

The FASEB journal, 2001-12, Vol.15 (14), p.2669-2679

2001

Volltextzugriff (PDF)

Model-based assessment of combination therapies - ranking of radiosensitizing agents in oncology

BMC cancer, 2023-05, Vol.23 (1), p.409-409, Article 409

2023

Volltextzugriff (PDF)

Glucosamine induces cell-cycle arrest and hypertrophy of mesangial cells: implication of gangliosides

Biochemical journal, 2005-06, Vol.388 (Pt 2), p.537-544

2005

Volltextzugriff (PDF)

Identification of a novel amidase motif in neutral ceramidase

Biochemical journal, 2006-02, Vol.393 (Pt 3), p.687-695

2006

Volltextzugriff (PDF)

Exposure-response modeling improves selection of radiation and radiosensitizer combinations

Journal of pharmacokinetics and pharmacodynamics, 2022-04, Vol.49 (2), p.167-178

2022

Volltextzugriff (PDF)

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

CPT: pharmacometrics and systems pharmacology, 2021-05, Vol.10 (5), p.428-440

2021

Volltextzugriff (PDF)

Bimodal Effect of Advanced Glycation End Products on Mesangial Cell Proliferation Is Mediated by Neutral Ceramidase Regulation and Endogenous Sphingolipids

The Journal of biological chemistry, 2004-08, Vol.279 (33), p.34343-34352

2004

Volltextzugriff (PDF)

Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels

FEBS letters, 2005-02, Vol.579 (5), p.1249-1254

2005

Volltextzugriff (PDF)

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide

CPT: pharmacometrics and systems pharmacology, 2018-12, Vol.7 (12), p.829-837

2018

Volltextzugriff (PDF)

Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies

Frontiers in immunology, 2014, Vol.5, p.233

2014

Volltextzugriff (PDF)

Molecular Cloning and Characterization of a Human Mitochondrial Ceramidase

The Journal of biological chemistry, 2000-07, Vol.275 (28), p.21508-21513

2000

Volltextzugriff (PDF)

Substrate specificity of rat brain ceramidase

Journal of lipid research, 2002-01, Vol.43 (1), p.141-148

2002

Volltextzugriff (PDF)

Hyperglycemia and glucosamine‐induced mesangial cell cycle arrest and hypertrophy: Common or independent mechanisms?

IUBMB life, 2006-07, Vol.58 (7), p.381-388

2006

Volltextzugriff (PDF)

A mitochondrial pool of sphingomyelin is involved in TNFα-induced Bax translocation to mitochondria

Biochemical journal, 2005-03, Vol.386 (3), p.445-451

2005

Volltextzugriff (PDF)

Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2

Pharmaceutical research, 2023-12, Vol.40 (12), p.3011-3023

2023

Volltextzugriff (PDF)

Purification and Characterization of a Membrane-bound Nonlysosomal Ceramidase from Rat Brain

The Journal of biological chemistry, 1999-09, Vol.274 (39), p.27948-27955

1999

Volltextzugriff (PDF)

Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1

Clinical pharmacology and therapeutics, 2020-09, Vol.108 (3), p.566-574

2020

Volltextzugriff (PDF)

Structural Requirements of Ceramide and Sphingosine Based Inhibitors of Mitochondrial Ceramidase

Biochemistry (Easton), 2001-08, Vol.40 (32), p.9657-9668

2001

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(47)
Dissertationen
(1)

Sprache

Englisch
(47)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents

Using thrombocytopenia modeling to investigate the mechanisms underlying platelet depletion induced by pan‐proteasome inhibitors

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases

Model‐Based Evaluation of Radiation and Radiosensitizing Agents in Oncology

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis

Model-based assessment of combination therapies - ranking of radiosensitizing agents in oncology

Glucosamine induces cell-cycle arrest and hypertrophy of mesangial cells: implication of gangliosides

Identification of a novel amidase motif in neutral ceramidase

Exposure-response modeling improves selection of radiation and radiosensitizer combinations

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

Bimodal Effect of Advanced Glycation End Products on Mesangial Cell Proliferation Is Mediated by Neutral Ceramidase Regulation and Endogenous Sphingolipids

Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide

Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies

Molecular Cloning and Characterization of a Human Mitochondrial Ceramidase

Substrate specificity of rat brain ceramidase

Hyperglycemia and glucosamine‐induced mesangial cell cycle arrest and hypertrophy: Common or independent mechanisms?

A mitochondrial pool of sphingomyelin is involved in TNFα-induced Bax translocation to mitochondria

Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2

Purification and Characterization of a Membrane-bound Nonlysosomal Ceramidase from Rat Brain

Characterization of Novel PI3KÎ´ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies

Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1

Structural Requirements of Ceramide and Sphingosine Based Inhibitors of Mitochondrial Ceramidase

Suchergebnisse filtern